Reneo Pharmaceuticals Inc. is halting development of its only asset, mavodelpar, after a phase IIb study missed its primary and secondary efficacy endpoints. The selective peroxisome proliferator-activated receptor (PPAR)-delta agonist was being developed to treat to rare genetic mitochondrial diseases.
Reneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Take 1 minute to subscribe and you ll get this story immediately, plus:
52 weekly issues
Book of Lists the most comprehensive business resource in San Diego
San Diego 500 influential business leaders you need to know Yours for only $99
First name: